Immune cell training may lead to new cancer therapies
NCT ID NCT05280379
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined how immune cells (myeloid cells and their bone marrow progenitors) change in patients with newly diagnosed thyroid or colon cancer. Researchers measured inflammatory markers before and after exposing cells to agents that could 'train' them to fight tumors. The goal was to better understand cancer-related inflammation and identify potential targets for future immunotherapies. No treatment was given to participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new immunotherapy approaches for cancers that don't respond to current treatments.
- What could go wrong
- This is a small, completed observational study with only 33 participants. It does not test any treatment, so any future therapies are highly uncertain and many years away.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
33 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of 30 participants with active colon carcinoma and 30 participants with active non-medullary thyroid carcinoma. All participants will undergo surgery.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * At least 18 years old and mentally competent * Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve * Planned to receive conventional treatment for the malignancy by surgery Exclusion Criteria: * Mentally incompetent * Pregnant or breastfeeding * Known inflammation or infectious disease or an immunosuppressive status * Using medication interfering with the immune system * Reduced platelets counts or other conditions associated with an increased risk of bleeding * Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas) * Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor * Serious psychiatric pathology * A self-reported alcohol consumption of \>21 units per week
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colon carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RadboudUMC
Nijmegen, Gelderland, 6525GA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new tracers make many cancers light up on scans?
- Massive cancer screening trial aims to cut deaths
- Why are young people getting cancer? a massive study aims to find out.
- New antibody shows promise in shrinking HER2+ colorectal tumors before surgery
- Hunt for hidden thyroid cancer genes ends early
- New Vaccine-Immunotherapy combo targets multiple cancers in early trial